Syneos Health (NASDAQ:SYNH) is scheduled to announce its earnings results before the market opens on Tuesday, November 6th. Analysts expect the company to announce earnings of $0.60 per share for the quarter. Investors interested in registering for the company’s conference call can do so using this link.
Syneos Health (NASDAQ:SYNH) last issued its earnings results on Thursday, August 2nd. The company reported $0.62 EPS for the quarter, beating the Zacks’ consensus estimate of $0.61 by $0.01. Syneos Health had a negative net margin of 4.32% and a positive return on equity of 7.80%. The business had revenue of $1.07 billion for the quarter, compared to the consensus estimate of $1.09 billion. The business’s quarterly revenue was up 315.5% on a year-over-year basis. On average, analysts expect Syneos Health to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.
Shares of SYNH stock opened at $46.50 on Monday. Syneos Health has a 52 week low of $31.10 and a 52 week high of $59.45. The company has a current ratio of 1.04, a quick ratio of 1.04 and a debt-to-equity ratio of 1.01. The firm has a market capitalization of $4.78 billion, a PE ratio of 23.97, a price-to-earnings-growth ratio of 1.10 and a beta of 0.94.
A number of equities analysts have recently commented on SYNH shares. UBS Group started coverage on shares of Syneos Health in a research note on Tuesday, October 9th. They issued a “buy” rating and a $60.00 target price on the stock. SunTrust Banks reissued a “buy” rating and issued a $60.00 target price on shares of Syneos Health in a research note on Friday, August 3rd. Mizuho reissued a “hold” rating and issued a $51.00 target price on shares of Syneos Health in a research note on Monday, August 6th. Barclays reissued a “hold” rating and issued a $51.00 target price (up previously from $43.00) on shares of Syneos Health in a research note on Friday, August 3rd. Finally, ValuEngine raised shares of Syneos Health from a “sell” rating to a “hold” rating in a research note on Saturday, September 22nd. Three equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $53.91.
About Syneos Health
Syneos Health, Inc operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various clinical development services spanning Phase I to Phase IV, including full-service global studies, as well as unbundled service offerings, such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with drug development process.
Read More: Buyback For Investors Defined
Receive News & Ratings for Syneos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneos Health and related companies with MarketBeat.com's FREE daily email newsletter.